High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$10.4M
$10,396,196
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2026-03-31 | $618,625 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2026-03-31 | $195,999 | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Savitz Ryan
• CFO
10b5-1 SellΔOwn -69.1%
2026-03-31
$5,017,220Whale
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 SellΔOwn -69.1%
|
2026-03-31 | $5,017,220Whale | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Savitz Ryan
• CFO
10b5-1 SellΔOwn -72.9%
2026-03-31
$1,646,493Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 SellΔOwn -72.9%
|
2026-03-31 | $1,646,493Large | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
Other
|
2026-03-31 | $627,657 | M | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
Other
|
2026-03-31 | $715,200 | M | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2026-03-31 | $108,879 | S | Form 4 |
|
DNTH
S
Dianthus Therapeutics, Inc. /DE/
Savitz Ryan
• CFO
10b5-1 SellΔOwn -19.3%
2026-03-31
$1,721,120Large
|
||||||
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 SellΔOwn -19.3%
|
2026-03-31 | $1,721,120Large | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2026-03-31 | $119,171 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2026-03-31 | $65,088 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
10b5-1 Sell
|
2025-12-04 | $903,600 | S | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
Equity Compensation
|
2025-12-04 | $0 | M | Form 4 |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
|
CFO
Other
|
2025-12-04 | $168,800 | M | Form 4 |